Industrifonden

Exciting news from our portfolio company BOOST Pharma, which has announced positive top-line clinical data from the Phase I/II BOOSTB4 study. BOOST Pharma is developing a novel therapy for Osteogenesis Imperfecta (OI), a rare genetic disease, and the results are truly promising.   The study demonstrated that the therapy is both safe and well tolerated in both prenatal and postnatal administration, and most impressively, it showed a 75% reduction in bone fracture rate – a central endpoint for patients and regulators alike. This is a significant breakthrough in the treatment of OI and sets BOOST Pharma’s therapy apart from anything else currently in development.   “This is the first and only treatment that can be given directly before and after birth, and that has shown such a large reduction in fracture rate. Fracture rate is the endpoint which really matters for patients as well as regulators. We look forward to the ongoing dialogues and seeing this treatment reach patients worldwide,” says Jonathan Ilicki, Board Director at BOOST Pharma and Principal at Industrifonden.   A huge congratulations to the BOOST Pharma team for this remarkable achievement! We look forward to seeing your continued success as this therapy progresses.   Read the full announcement below.

Cellevate AB has successfully closed its second seed round, raising 3.2 MEUR to accelerate global commercialization! Cellevate, a cutting-edge biotech company developing next-generation cell culture systems to revolutionize biomanufacturing, secured the funding through a round led by Industrifonden, in syndication with the European Innovation Council Fund (EIC Fund). Mala Valroy, Investment Manager at Industrifonden and Board member of Cellevate, commented: “We are impressed with the progress the team has made in preparing the product and company for a successful commercial launch. This investment positions the company to begin its international expansion and help customers achieve the highest yield and productivity improvements in upstream bioprocessing for gene therapies.” This is a major milestone for Cellevate AB as they move toward transforming the future of cell culture and scaling their innovative solutions worldwide. We are excited to support their journey and look forward to seeing their global impact unfold!

Excited to announce that Mala Valroy will be moderating the AI Supersession at NLSDays 2024, where we’ll explore the convergence of #LifeScience and #healthcare in the age of #AI. Jonas Jendi, Jonathan Ilicki, Fredrik Lehmann, and Sara Jawad will also be attending the event. We are looking forward to insightful discussions and great connections at one of the leading events in Nordic life sciences!

For over 15 years, Ny Teknik’s 33-listan has highlighted Sweden's most innovative young tech companies. Last week, Ny Teknik hosted the Unicorn Reunion, an alumni event for 33-list companies, where startups and investors gathered to exchange ideas and explore new opportunities. Anna Haupt and Sara Frykstrand Ångström, MSc, PhD, were there to connect and it was inspiring to see the continued growth and innovation coming from the 33-list community. Read more about the event and hear insights from Sara Frykstrand in this article: https://lnkd.in/gTDb7S9G

Patrik Sobocki (MSc, PhD) and Mala Valroy will be attending The Drop on September 16-17 in Malmö – Europe's leading climate tech festival. This vibrant event will gather over a thousand attendees from across the globe, all focused on addressing the pressing climate challenges of our time. We're looking forward to engaging with the community and exploring impactful solutions that can lead to a more sustainable future.

As we navigate through a world of unprecedented challenges – from climate crises to social inequalities – it's clear that innovation and collaboration are key. That's why we're thrilled to be part of TechBBQ a vibrant arena where founders, investors, and changemakers converge to shape our collective future. This year, we embrace the theme "One Giant Leap," reflecting our commitment to bold moves and transformative impacts. The event is taking place today and tomorrow so make sure to reach out to our team at the event Caroline Wadstein Andreas Söneby Rebecka Kornfeld Clara Norgren Tobias Elmquist

We are thrilled to announce that our portfolio company, Calliditas Therapeutics, has been acquired by the Japanese multinational Asahi Kasei Corporation in a $1.1 billion deal! Calliditas has been a pioneer in developing treatments for rare renal and hepatic diseases. Industrifonden was one of the first investors in Calliditas and has supported the company’s efforts to reach leadership in IgA nephropathy. Patrik Sobocki (MSc, PhD), Senior Investment Director at Industrifonden, commented: "Calliditas is one of the most successful exits in Industrifonden's history and the team at Industrifonden is proud to have contributed to the journey. The success reflects the hard work and dedication of the Calliditas team in developing life-changing treatments for patients worldwide. We are delighted to see Asahi Kasei recognize the value that Calliditas brings to the global healthcare landscape." We congratulate the entire Calliditas team on this remarkable achievement. This milestone not only underscores their dedication to improving patients' lives but also reinforces our commitment at Industrifonden to supporting companies that are making a real difference in the world.

Congratulations to Asgard Therapeutics on the publication of their recent study in Science. The research, co-led with the Pereira Lab, demonstrates the potential of reprogramming tumor cells into antigen-presenting dendritic cells in vivo, offering new insights into cancer immunotherapy. Asgard is now preparing for Phase I/II trials with their lead candidate, AT-108, as part of their clinical development efforts.

The Future of Swedish and Danish Life Science - in two words?    It's bright.   It's also the name of a conference that took place last week, uniting talent in Medicon Village, a focal point between Sweden's and Denmark's life science clusters.    Our principal Jonathan Ilicki was invited to the panel on "What is the next hype after obesity?", together with Sanne Brun Jensen from BII and Duarte Marchand from Johnson & Johnson.   The discussion covered if and how the tough financing climate is developing, what areas are over- and underrated right now, and advice on how to raise money during the coming 12-18 months.    Jonathan enjoyed the conference: "It was inspiring to meet passionate life science leaders who are set on changing the world, as well as seasoned veterans candidly sharing their hard-earned learnings."

We’re happy to welcome Lina Jorheden as acting CEO at SaltX Technology. With her extensive industry experience, Lina is set to propel SaltX into their next phase of growth as they aim for zero emissions in heavy industries. In addition, SaltX has secured MSEK 20 from Industrifonden and SMA Mineral to advance our Electric Arc Calciner technology, targeting major CO2 reduction in the lime and cement sectors. Tobias Elmquist, Senior Investment Director at Industrifonden, commented; "We are enthusiastic about Lina's vision for SaltX as the company moves into a vital phase of industrialization and commercialization. Her ability to lead is essential for their goal of achieving a zero-emission future in heavy industries." Join us in congratulating Lina and the whole team at SaltX Technology!